FDA approves first JAK inhibitor for UC

Approval of tofacitinib (Xeljanz) for ulcerative colitis has been recommended by a unanimous vote of the FDA’s Gastrointestinal Drugs Advisory Committee. The JAK inhibitor is the first in its class to be recommended for adults living with moderately to severely active ulcerative colitis. The committee voted 15-0 in favour of the extension of the use of ...

Already a member?

Login to keep reading.

© 2021 the limbic